Hartritmestoornissen (QT-verlenging op het ECG) door domperidon

In literature, domperidone has been linked to QT-prolongation resulting in acute cardial dysrythmias and sudden death. However, in practice doctors are still in need of domperidone. We hypothesize that in normal dosages QT-prolongation is relatively infrequent and we expect we can identify clear risk factors that may guide doctors in safe prescribing of domperidone. In order to test this hypothesis, an observational study will be designed. All patients aged 18 years and older who start with domperidone while hospitalised in the Erasmus MC will be included. Excluded are patients who do not give informed consent, who are incompetent and who suffer from the congenital prolonged QT-syndrome.

Primary outcome will be QT time on the ECG, performed 30-60 minutes after the fourth dosage of domperidone. Secondary outcome will be a continuous QT-time measurement during 24 hours, starting after the fourth dosage.

We will look into the following potential risk factors:

- serum concentration of domperidone 30-60 minutes after the fourth dosage of domperidone

- pharmacogenetics (CYP3A4, CYP1A2, CYP2E1)

- general patient characteristics (age, gender, body weight, comorbidities, renal and hepatic function, serum electrolyte parameters)

- domperidone dosage

- comedication.

We expect to include 300 patients in one year.

In literature, domperidone has been linked to QT-prolongation resulting in acute cardial dysrythmias and sudden death. However, in practice doctors are still in need of domperidone. We hypothesize that in normal dosages QT-prolongation is relatively infrequent and we expect we can identify clear risk factors that may guide doctors in safe prescribing of domperidone.

1-2 days after starting domperidone.

None. It concerns an observational study.
Domperidone is prescribed as part of usual care.